Today is the "Triple Witching Day" of the US stock market, which occurs only four times a year, specifically on the third Friday of March, June, September, and December. This day marks the simultaneous settlement of three major derivative contracts (stock index futures, stock index options, and individual stock options), and volatility is expected to be significant, so be cautious ⚠️.

At these times, many institutions in the US often begin to rebalance their positions, as funds are returned and new allocations are made. As retail investors, we can follow the smart money and take action together, making a comprehensive adjustment to our stock holdings by taking profits on high-risk stocks that are currently profitable and reallocating to promising sectors.

Recently, we reminded about Oracle's CDS (Credit Default Swap) soaring to a historical high, indicating potential debt default risks; compounded by the recent breakdown of negotiations with a key partner, Blue Owl Capital, regarding up to $10 billion in financing, this has caused a series of market concerns about the significant disparity between the debt pressure from AI capital investments and potential profit recovery, sparking discussions about an AI bubble.

Additionally, I looked at the latest market capitalization density of the "Seven Stars" of the US stock market (as shown in Figure 1), which has also reached a high level. The total market capitalization of the seven tech giants is currently $20.87 trillion, accounting for over 58% of the Nasdaq. Overall, the trading channels and potential of AI tech stocks are relatively crowded. If you are an institutional investor, which sectors would you adjust your positions in after this "Triple Witching Day" settlement?

From my current consideration logic, I prioritize sectors with relatively low price-to-earnings ratios, high dividends, and stable growth potential, regardless of economic prosperity or recession—industries that the public needs to use, such as biopharmaceuticals. From past market adjustments, the biopharmaceutical sector has shown relatively strong performance, especially companies like Eli Lilly that focus on weight loss drugs. Here, I list five biopharmaceutical companies that I am very optimistic about for your reference:

1️⃣ #EliLilly (Eli Lilly, #LLY) Weight loss drugs are a good business

• Main business: #EliLilly is a well-established American multinational pharmaceutical company founded in 1876. Eli Lilly conducts large-scale clinical trials in 55 countries worldwide, with products sold in about 120 countries. Its core products mainly include traditional prescription drugs for diabetes, central nervous system/mental health, and cancer, but the biggest highlight in recent years has been its strong rise in the anti-obesity and GLP-1 (and new generation dual/triple agonists) markets, leading to explosive revenue growth. Lilly is seen by many reports as one of the leaders in the weight loss drug sector by 2025.

• Revenue: Q3 2025 revenue is approximately $17.6B (quarterly), with quarterly revenue and earnings per share exceeding expectations. The dividend yield is low at only 0.69%, with most revenue focused on R&D.

• Key drugs: Diabetes and weight loss drugs (GLP-1/GIP receptor agonists, etc.), Mounjaro for treating type 2 diabetes, which also shows significant effects in weight loss. Trulicity (Dulaglutide) is a best-selling type 2 diabetes drug. Zepbound (Tirzepatide) is used for weight loss indications. Jardiance (Empagliflozin) treats type 2 diabetes and heart failure. Insulin products: such as Humalog and Humulin. Alzheimer's disease (in research/pending approval), Donanemab is an investigational drug for treating Alzheimer's disease, expected to be one of the key drugs in the future. Other investigational or new drugs, Orforglipron is an oral small molecule GLP-1 receptor agonist with potential in diabetes and weight loss.

• Future expectations: The current logic is "weight loss/GLP-1 profits + pipeline continues to expand." As long as new drugs continue to show better efficacy, reimbursement and supply chain issues are controllable, Lilly's revenue can continue to grow; but risks include regulatory pressures, pricing pressures, insurance restrictions, and competition (especially from Novo Nordisk and other competitors) that may erode margins. In simple terms, Lilly is the current "box office star," but whether the box office can be sustained depends on insurance and competition.

2️⃣ #AstraZeneca (AstraZeneca, #AZN) Cancer expert

• Main business: #AstraZeneca is a large British pharmaceutical company that primarily profits from oncology, respiratory/immunology, cardiovascular metabolism, and vaccines. Recently, there has been significant progress in ADC (antibody-drug conjugates) for breast cancer/triple-negative breast cancer, with favorable clinical data that has substantial revenue-driving potential and imaginative space.

• Revenue: Q3 2025 revenue is approximately $151.9B (quarterly), with quarterly revenue and earnings per share exceeding expectations. The dividend yield is low at only 2.3%, with most revenue focused on R&D.

• Key drugs: In the oncology field, Faslodex (injection) and others; cardiovascular, renal, and metabolic drugs, Evusheld (AZD7442), baxdrostat, AZD0780, etc.; respiratory and immunology drugs; neuroscience (mental illness) drugs, Seroquel XR (Seroquel XR) and others.

• Future expectations: #AstraZeneca is like a company making "steady bets on new cancer drugs"—if the Enhertu series, Datroway, and other blockbuster drugs can truly expand in the coming years, the company can continue to outperform the market; if clinical or regulatory issues arise, growth may revert to "old pharmaceutical company" levels. In short, clinical milestones will determine #AstraZeneca's future direction.

3️⃣ #Pfizer (Pfizer, #PFE) Benefiting from flu outbreak season

• Main business: Pfizer is one of the largest pharmaceutical companies in the world, with operations in drug research and development, vaccines, consumer healthcare products, and more. It has a presence in multiple fields, including vaccines (including pneumococcal vaccines), oncology, cardiovascular, diabetes/metabolic diseases, etc. During the COVID-19 pandemic, its vaccine and oral drug Paxlovid received significant attention, but as the pandemic eased, this revenue has significantly declined. Overall, Pfizer has both "stable cash flow" (mature products, vaccines) and "platform + explosive points" (mRNA, antibody drugs, ADC collaborations), making it quite comprehensive.

• Revenue: Q3 2025 revenue is approximately $16.6B (quarterly), with the company performing steadily in the first half of 2025 and adjusting its EPS guidance. Notably, Pfizer's dividend is very stable, with a yield of about 6.8%, higher than US Treasury yields.

• Key drugs: Comirnaty (COVID-19 mRNA vaccine, in collaboration with BioNTech), Padcev (ADC in collaboration with Astellas), and several investigational assets (including seasonal vaccine products and cancer combinations). Recently, the combination of Padcev + Keytruda has shown highlights at academic conferences, potentially driving the expansion of indications.

• Future expectations: Vaccines (regulatory/market launch of seasonal vaccine formulations), new indication data for Padcev combination therapy, and important Phase 3 topline approvals in the company's pipeline.

4️⃣ #Regeneron (Regeneron Pharmaceuticals, #REGN) "Cash cow" in the ophthalmology field

• Main business: #Regeneron is an American pharmaceutical company founded in 1988. Initially focused on neurotrophic factors and their regenerative capabilities, it later began researching cytokines and other areas. It is a typical "innovative biopharmaceutical company," with a few high-margin drugs (like EYLEA) serving as cash cows, and new products can quickly drive valuation. The company has significant market share in ophthalmic diseases, allergic and inflammatory diseases, cancer, cardiovascular, and metabolic diseases.

• Revenue: Q3 2025 revenue is approximately $3.75B (quarterly), with quarterly revenue and earnings per share falling short of expectations. The dividend yield is low at only 0.31%, and the company has a buyback plan. The volatility is largely due to EYLEA and other drugs being the main drivers, with significant fluctuations in product sales and rising costs raising performance concerns.

• Key drugs: Dupixent (dupilumab) for treating moderate to severe atopic dermatitis. EYLEA (aflibercept) / EYLEA HD (aflibercept) injection for treating various ophthalmic diseases, including wet age-related macular degeneration (Wet AMD), diabetic macular edema, and macular edema caused by retinal vein occlusion. Libtayo (cemiplimab), an immune checkpoint inhibitor (PD-1 inhibitor), for treating certain skin squamous cell carcinomas and other specific cancers. Praluent (alirocumab) for treating hypercholesterolemia.

• Future expectations: Progress on the FDA review of EYLEA HD, which, if approved, could stimulate the volume of EYLEA-related products. Key applications for drugs like odronextamab, if approved, would also help the company's profit growth.

5️⃣ #NovoNordisk (Novo Nordisk, #NVO) Eli Lilly's competitor

• Main business: #NovoNordisk is a Danish biopharmaceutical company founded in 1923, focusing on the research, production, and sales of treatment drugs for serious chronic diseases such as diabetes and obesity. It holds a leading position in the global diabetes treatment market, providing insulin, GLP-1 therapies, and other products, while also operating a biopharmaceutical division offering treatments for hemophilia and growth hormone. Among these, diabetes and weight loss drugs (GLP-1 series) are absolutely core, with Wegovy and Ozempic making Novo a leader in the weight loss and diabetes fields.

• Revenue: Q2 2025 revenue is approximately $74.9B (quarterly), with quarterly revenue and earnings per share falling short of expectations. The dividend yield is decent at 3.22%, and the company has a buyback plan. The stock has seen a significant decline over the past year, mainly due to intense competition in the weight loss drug sector and a severe tilt in business, with diabetes and weight loss drugs accounting for 93% of its main business.

• Key drugs: Ozempic, a GLP-1 (glucagon-like peptide-1) receptor agonist for treating type 2 diabetes. Wegovy, a high-dose version of Ozempic, specifically approved for chronic weight management (weight loss). Oral semaglutide: Novo Nordisk also excels in oral GLP-1 drugs.

• Future expectations: Novo is currently the "GLP-1 leader," with long-term pricing power and channel advantages; however, caution is needed: the market share may be eroded by competitors (such as Eli Lilly), and there may be issues with insurance pricing or supply chains. If the company can maintain its lead through new indications, oral drugs, or better commercialization, the long-term outlook remains very solid.

Overall, following institutional players to rebalance positions on "Triple Witching Day" and enjoying the Christmas 🎄 market rally is a smart strategy and method. As the saying goes, "trees move and die, people move and live." The flexibility of the US stock market allows us to adjust positions across different sectors in response to varying risk preferences, which may be the key factor in our ability to thrive in the market. 🧐

Currently, these companies are all available on #MSX (as shown in Figure 2, specifically for the pharmaceutical sector). When trading US stocks, I choose to use the #RWA tokenized platform #MSX. Recently, MSX also has a 🎄 Christmas event, first come, first served, so come and participate to invest in the US stock market: http://msx.com/?code=Vu2v44

Early US stock investment fans and partners can message me privately. After filling out the form, you can enter the US stock discussion and exploration community for free (currently limited to 10 people per week, assistant review may take some time, thank you 🙏)!

免责声明：本文章仅代表作者个人观点，不代表本平台的立场和观点。本文章仅供信息分享，不构成对任何人的任何投资建议。用户与作者之间的任何争议，与本平台无关。如网页中刊载的文章或图片涉及侵权，请提供相关的权利证明和身份证明发送邮件到support@aicoin.com，本平台相关工作人员将会进行核查。